(Q43041294)

12 November 2017

title

Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus (English)

1 reference

12 November 2017

1 reference

1 reference

1 reference

1 reference

Nezam H Afdhal

6

0 references

author name string

John G McHutchison

1

1 reference

12 November 2017

Bruce R Bacon

2

1 reference

12 November 2017

Stuart C Gordon

3

1 reference

12 November 2017

Eric Lawitz

4

1 reference

12 November 2017

Mitchell Shiffman

5

1 reference

12 November 2017

Ira M Jacobson

7

1 reference

12 November 2017

Andrew Muir

8

1 reference

12 November 2017

Mohammed Al-Adhami

9

1 reference

12 November 2017

Mary L Morris

10

1 reference

12 November 2017

Julie A Lekstrom-Himes

11

1 reference

12 November 2017

Susan M Efler

12

1 reference

12 November 2017

Heather L Davis

13

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

12 November 2017

1 reference

12 November 2017

volume

46

1 reference

12 November 2017

issue

5

1 reference

12 November 2017

page(s)

1341-1349

1 reference

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

12 November 2017

cites work

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

The hepatitis C virus persistence: how to evade the immune system?

21 January 2018

1 reference

Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition

21 January 2018

1 reference

Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.

21 January 2018

1 reference

Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy

21 January 2018

1 reference

Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation

21 January 2018

1 reference

Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.

21 January 2018

1 reference

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).

21 January 2018

1 reference

Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon

21 January 2018

1 reference

Therapeutic potential of Toll-like receptor 9 activation

21 January 2018

1 reference

The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice

21 January 2018

1 reference

The natural history of chronic hepatitis C infection.

21 January 2018

1 reference

7 January 2021

Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

7 January 2021

Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides

1 reference

7 January 2021

Quantification of Oligodeoxynucleotides in Human Plasma with a Novel Hybridization Assay Offers Greatly Enhanced Sensitivity over Capillary Gel Electrophoresis

1 reference

7 January 2021

Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist

1 reference

7 January 2021

Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21773

1 reference

12 November 2017

1 reference